Scinai Immunotherapeutics Ltd ADR (SCNI)

Currency in USD
1.230
+0.070(+6.03%)
Closed·
1.150-0.080(-6.50%)
·
Unusual Post-Market activity
SCNI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.1401.760
52 wk Range
1.06015.650
Key Statistics
Prev. Close
1.23
Open
1.56
Day's Range
1.14-1.76
52 wk Range
1.06-15.65
Volume
64.1M
Average Volume (3m)
2.06M
1-Year Change
-91.0219%
Book Value / Share
15.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SCNI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low Price / Book multiple
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Scinai Immunotherapeutics Ltd ADR Earnings Call Summary for Q2/2026

  • H1 2026 revenue rose 22.7% to $949K following Recipharm Israel acquisition, but operating loss hit $4.6M and gross loss reached $2.37M.
  • Reported net income of $1.57M driven by one-time $6.4M bargain purchase gain; underlying business remains unprofitable with -252% gross margin.
  • Cash position stands at $2.85M as of June 30; committed customer orders total $3.1M with $2.1M invoiced, raising liquidity concerns amid dilution risk.
  • Management maintains 2026 CDMO revenue target of $5M, contingent on project execution and converting customer commitments into recognized revenue.
  • CEO emphasized strategic shift post-acquisition, combining immunology R&D with manufacturing capabilities while prioritizing non-dilutive funding options.
Last Updated: 2026-08-26, 11:42 a/m
Read Full Transcript

Earnings

Latest Release
Aug 24, 2026
EPS / Forecast
-1.77 / --
Revenue / Forecast
460K / --
EPS Revisions
Last 90 days

SCNI Income Statement

Compare SCNI to Peers and Sector

Metrics to compare
SCNI
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.5x−0.3x
PEG Ratio
0.00−0.030.00
Price/Book
0.1x1.2x2.6x
Price / LTM Sales
0.5x12.0x2.9x
Upside (Analyst Target)
-370.9%63.9%
Fair Value Upside
Unlock2.4%9.4%Unlock

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.

People Also Watch

2.8900
TNON
-3.02%
0.510
OLB
-22.01%
0.4596
WHLR
+0.35%
1.0550
RETO
-7.46%

FAQ

What Is the Scinai ADR (SCNI) Stock Price Today?

The Scinai ADR stock price today is 1.230 USD.

What Stock Exchange Does Scinai ADR Trade On?

Scinai ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Scinai ADR?

The stock symbol for Scinai ADR is "SCNI."

What Is the Scinai ADR Market Cap?

As of today, Scinai ADR market cap is 701.130K USD.

What Is Scinai ADR's Earnings Per Share (TTM)?

The Scinai ADR EPS (TTM) is -4.892.

From a Technical Analysis Perspective, Is SCNI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Scinai ADR Stock Split?

Scinai ADR has split 3 times.

How Many Employees Does Scinai ADR Have?

Scinai ADR has 45 employees.

What is the current trading status of Scinai ADR (SCNI)?

As of Oct 14, 2026, Scinai ADR (SCNI) is trading at a price of 1.230 USD, with a previous close of 1.230 USD. The stock has fluctuated within a day range of 1.140 USD to 1.760 USD, while its 52-week range spans from 1.060 USD to 15.650 USD.

What Is the SCNI Premarket Price?

SCNI's last pre-market stock price is 1.550 USD. The pre-market share volume is 43,390,000.000, and the stock has decreased by 0.390, or 33.620%.

What Is the SCNI After Hours Price?

SCNI's last after hours stock price is 1.150 USD, the stock has decreased by -0.080, or -6.500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.